Elutia Inc Ordinary Shares - Class A ELUT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
Trading Information
- Previous Close Price
- $0.82
- Day Range
- $0.82–0.84
- 52-Week Range
- $0.50–1.39
- Bid/Ask
- $0.81 / $0.85
- Shares Outstanding
- 44.40M
- Market Cap
- $37.29M
- Volume/Avg
- 39,710 / 182,915
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.57
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- < 0.01%
Company Profile
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 26
- Website
- https://www.elutia.com
Valuation
Metric | ELUT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.38 |
Price/Sales | 5.57 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ELUT |
|---|---|
Quick Ratio | 2.56 |
Current Ratio | 2.63 |
Interest Coverage | — |
Quick Ratio
ELUT
Profitability
Metric | ELUT |
|---|---|
Return on Assets (Normalized) | −180.17% |
Return on Equity (Normalized) | −1,151.89% |
Return on Invested Capital (Normalized) | −468.49% |
Return on Assets
ELUT
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|$G?^crt | LOCK|QS@q@ | $188B | |||
| Medtronic PLC MDT | LOCK|R!>^<$ | LOCK|TrR$ | $132B | |||
| Stryker Corp SYK | LOCK|$rxwwFBm | LOCK|H^ | $118B | |||
| Boston Scientific Corp BSX | LOCK|Z?V#$>q | LOCK|&LVy | $64B | |||
| Edwards Lifesciences Corp EW | LOCK|Y>w&^!p | LOCK|$h#c | $62B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|bg<DFvc | LOCK|NBq | $38B | |||
| DexCom Inc DXCM | LOCK|Y?!$xMq# | LOCK|mK&P | $31B | |||
| Koninklijke Philips NV ADR PHG | LOCK|>G | LOCK|t& | $30B | |||
| Steris PLC STE | LOCK|Y#>%Z< | LOCK|>QGf | $26B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|?!JR^j! | LOCK|#j | $20B |